Peptide therapy TikTok claims: what the science actually supports

What did @thegutcode actually say?

The creator argued that BPC-157 poses a "potential tumor growth risk" because it upregulates VEGF, a protein that promotes blood vessel formation. They pointed out that some cancer treatments work by blocking VEGF, and concluded that BPC-157 does "the exact opposite," making it something people concerned about cancer should avoid.

To be fair, this is a more responsible framing than most BPC-157 content on TikTok. The creator isn't selling anything here. They're flagging a theoretical oncological concern that deserves a real look, even if the reasoning has some gaps worth examining.

Does the science back this up?

Partially, but the picture is more complicated than a clean cause-and-effect story. Yes, BPC-157 promotes angiogenesis partly through VEGF pathways. But the leap from "raises VEGF" to "feeds tumors" oversimplifies how cancer biology actually works.

A 2018 review by Chang et al. in Current Pharmaceutical Design noted that BPC-157 demonstrates angiogenic properties in wound healing models, consistent with VEGF involvement. However, the same review acknowledged that several animal studies have observed anti-tumor effects in certain cancer models, complicating a straightforward "pro-tumor" narrative.

VEGF inhibition via drugs like bevacizumab (the creator likely means this when saying "vaston," which is not a standard medical term) is a real and established oncology strategy. But VEGF is not universally cancer-promoting. Its role is context-dependent, varying by tumor type, stage, and microenvironment. Calling BPC-157 the "exact opposite" of anti-cancer therapy is a rhetorical shortcut that doesn't hold up under scrutiny.

What did they get wrong (or right)?

They got the core mechanism right: BPC-157 does appear to increase VEGF expression in preclinical models, and VEGF inhibition is genuinely used in oncology. That part earns credit. Where the reasoning breaks down is in the linear extrapolation.

First, all available evidence on BPC-157 and cancer is preclinical. There are no human trials evaluating BPC-157's effect on tumor growth, full stop. Making clinical risk assessments based on cell culture and rodent data alone is speculative, even when well-intentioned.

Second, the creator uses "vaston" as a drug name, which does not correspond to any approved medication. The likely reference is bevacizumab (Avastin), a VEGF-targeting monoclonal antibody. Getting the drug name wrong doesn't invalidate the argument, but it signals a loose relationship with clinical specifics.

Third, and most importantly: some animal studies have actually shown BPC-157 inhibiting tumor growth in specific models. Sikiric et al. (2020, Journal of Physiology Paris) described cytoprotective and anti-inflammatory properties that could theoretically oppose tumorigenesis in some contexts. This does not mean BPC-157 is safe for cancer patients. It means the biology is genuinely ambiguous, not a one-way street toward tumor promotion.

What should you actually know?

The creator's bottom-line recommendation, that people with cancer or tumor concerns should be cautious with BPC-157, is reasonable. The reasoning used to get there is partially flawed, but the conclusion itself is defensible given the current evidence gap.

BPC-157 has not been tested in human cancer patients. It is not FDA-approved. Any use occurs outside of clinical trials, which means no one has systematically studied what happens when someone with an active malignancy takes it. That uncertainty alone is sufficient reason for caution, without needing to overclaim a confirmed VEGF-driven tumor risk.

If you are currently undergoing cancer treatment or monitoring, the appropriate step is a conversation with your oncologist before considering any peptide, supplement, or off-label compound. A responsible telehealth provider will not prescribe BPC-157 to patients with active cancer or a history of malignancy, precisely because the risk profile is unknown, not because the mechanism has been definitively proven harmful.

• No human data exists on BPC-157 and cancer outcomes.
• VEGF upregulation is not automatically equivalent to tumor promotion.
• Some preclinical models show anti-tumor properties, adding genuine uncertainty.
• The caution advised is appropriate even if the mechanistic argument is oversimplified.